Q1 2025 Altimmune Inc Earnings Call Transcript
Key Points
- Altimmune Inc (ALT) is optimistic about the upcoming readout of their IMPACT Phase 2b NASH trial, expecting to achieve key efficacy and safety objectives.
- The company has entered into a $100 million credit facility with Hercules Capital, enhancing financial flexibility for the development of pemvidutide.
- Altimmune Inc (ALT) is expanding its clinical trials to include alcohol use disorder (AUD) and alcohol liver disease (ALD), addressing significant unmet medical needs.
- The company reported a strong cash position, ending the first quarter with $150 million in cash, cash equivalents, and short-term investments.
- Altimmune Inc (ALT) is preparing for a Phase 3 trial in NASH, with plans to hold an end of Phase 2 meeting with the FDA in the fourth quarter of 2025.
- The company faces risks and uncertainties that could cause actual results to differ materially from forward-looking statements.
- R&D expenses decreased from $21.5 million in Q1 2024 to $15.8 million in Q1 2025, which might indicate reduced investment in research and development.
- Net loss for the first quarter of 2025 was $19.6 million, indicating ongoing financial challenges.
- The company is still in the process of rereading biopsies for the IMPACT trial, which could affect the timeline and outcomes.
- There is uncertainty regarding the placebo response rate in the IMPACT trial, which could impact the trial's success.
Good day, ladies and gentlemen, and welcome to Altimmune First Quarter 2025 Financial Results Conference Call. After the speakers' presentation, there will be a question-and-answer session. (Operator Instructions) As a reminder, this call is being recorded.
Iâll now introduce your host for today's conference call, Lee Roth, President of Burns McClellan, Investor Relations Advisors to Altimmune. Lee, you may begin.
Thanks Gigi. Good morning everyone. Once again thank you all for joining us for Altimmuneâs first quarter 2025 financial results and business update conference call.
On todayâs call you will hear from Dr. Vipin Garg, our Chief Executive Officer; Dr. Scott Harris, our Chief Medical Officer; and Greg Weaver, our Chief Financial Officer. Dr. Scot Roberts, our Chief Scientific Officer and Ray Jordt, our Chief Business Officer will join us for the Q&A session.
Our first quarter 2025 results and corporate update press release was issued earlier this morning and can be
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
